Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio
Business Exposures
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
99 100 Next >
FDA Rejects MDMA for Mental Health Treatment After Identifying Flawed Study Data
Via Press Release Distribution Service
Exposures Product Safety
Lykos Therapeutics Strategic Reorganization Following FDA's Decision Rejecting MDMA For PTSD Treatment
Via Benzinga
Exposures Product Safety
Incyte Seeks Expanded FDA Approval For Lymphoma Drug After Releasing Promising Topline Data From Late-Stage Study
Via Benzinga
Exposures Product Safety
Tickers INCY
FDA Approves AstraZeneca's Blockbuster Cancer Drug, Imfinzi, In Combination With Chemo For Non-Small Cell Lung Cancer
Via Benzinga
Exposures Product Safety
Tickers AZN
From Detroit Dreams to Hollywood Realities: Anise Fuller’s Journey with Walk By Faith Productions
Via Small Business Trendsetters
Topics Product Recall
Exposures Legal Product Safety
The Benefits of Genetic Testing for Patients with CDKL5 Deficiency Disorder and Other Rare Genetic Epilepsies
Via Brandpoint
Exposures Product Safety
Steven Gillhouse Featured in Exclusive Interview on Ideamensch
Via Get News
Topics Product Recall
Exposures Legal Product Safety
Electrically Altering Children's Brains: Psychiatry's Latest Treatment Fad
Via PRLog
Exposures Product Safety
Why Is Small-Cap Tempest Therapeutics Stock Trading Higher On Thursday?
Via Benzinga
Exposures Product Safety
Tickers RHHBY TPST
BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Releases Q2 2024 Financial Report, Operational Update
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
Tickers BEAT
InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Reports on Q2 2024 Financial Results, Business Highlights
Via Investor Brand Network
Exposures Product Safety
Tickers LGVN
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Publishes Q2 2024 Results
Via Investor Brand Network
Exposures Product Safety
Tickers CNSP
FDA Rejects MDMA Therapy Application, Calls for More Research
Via Investor Brand Network
Exposures Product Safety
FDA Approves Incyte/Syndax Partnered Drug For Chronic Graft-Versus-Host Disease, A Post-Transplant Complication
Via Benzinga
Exposures Product Safety
Tickers INCY SNDX
FDA Approves Gilead's Seladelpar For Inflammatory Liver Disease, Acquired Via $4B CymaBay Deal
Via Benzinga
Exposures Product Safety
Tickers GILD
ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements
Via NewMediaWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Tickers ABVC
“Explosive Growth Stocks: Innovations, Strategy, Earners Unlock Prime Potential CXAI, OGEN, PRSO, INBS, KAVL”
Via AB Newswire
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
Tickers CXAI INBS OGEN PRSO
Substantial Funding, Debt Resolution, HOPE Dividend, Successful Clinical Trial Towards Accelerated Drug Approval for Bipolar Depression: Nasdaq: NRXP
Via PRLog
Topics Regulatory Compliance
Exposures Legal Product Safety Regulatory
Tickers NRXP
Don't Promote Copycat Weight-Loss Drugs Amid Improved Supply, Eli Lilly Asks Doctors, FDA Evaluates
Via Benzinga
Exposures Product Safety
Tickers LLY NVO
Kaya Holdings Advocates For Psilocybin As FDA Rejects MDMA For PTSD Treatment
Via Benzinga
Exposures Product Safety
Tickers KAYS
Ford Recalls Over 37,000 Vehicles, Including Mustang Mach-E EV SUV, Due To Non-Operational Front Windshield Wipers
Via Benzinga
Topics Product Recall
Exposures Legal Product Safety
Tickers F
Custics Singapore’s Hautuki Arrives at Incheon International Airport Duty-Free Shop
Via Binary News Network
Exposures Product Safety
Advanced Hood Cleaning Solutions Enhances Commercial Kitchen Safety with Comprehensive Cleaning and Maintenance Services
Via Get News
Exposures Product Safety
MDMA Therapy Papers Retracted Amid Ethical Concerns At Lykos Study Site
Via Benzinga
Exposures Product Safety
FDA Backs Off Joint Study On Kratom And Psychedelics Amidst Public Criticism
Via Benzinga
Exposures Product Safety
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Holds Initial Breakthrough Therapy Meeting with FDA, Plans for CYB003 Phase 3 Trial
Via Investor Brand Network
Exposures Product Safety
Tickers CYBN
GM Recalls Nearly 22,000 Cadillac Lyriq Electric SUVs Due To Concerns About Loss Of Braking Ability
Via Benzinga
Topics Product Recall
Exposures Legal Product Safety
Tickers GM
Shock-Gard CEO Matthew Bullock: Driving Innovation from Philadelphia to Miami
Via Zexprwire
Topics Product Recall
Exposures Legal Product Safety
CCHR Commends FDA Decision: Psychedelic Drug Ecstasy Not Proven Safe or Effective Treatment for Traumatized Patients
Via Press Release Distribution Service
Exposures Product Safety
Ascendis' Hypoparathyroidism Drug Scores FDA Approval As First and Only Treatment, Replacing Takeda's Drug Discontinued Due To Supply Issues
Via Benzinga
Exposures Product Safety
Tickers ASND TAK
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.